Novo Nordisk files etavopivat for US and EU approval in sickle cell disease
Novo Nordisk has sent its sickle cell drug etavopivat, dosed once a day, to US and EU regulators, based on Phase 3 HIBISCUS data. Reuters reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Novo Nordisk has submitted a new drug application to the US FDA and a marketing authorisation application to the European Medicines Agency for etavopivat, an experimental treatment for sickle cell disease. The drug is taken once a day and is intended for teenagers and adults with the condition, and the filings rely on efficacy and safety data from the Phase 3 HIBISCUS trial, according to Reuters.
The FDA has granted fast track, rare pediatric disease and orphan drug designations, with action expected in 2027. The European Commission has also granted orphan drug designation, and an EMA decision is likewise expected in 2027. In the trial, the drug reduced vaso-occlusive crises by 27% and delayed the first such crisis by roughly four months.
why it matters
Regulatory decisions are not due until 2027, so the filings are a pipeline step for Novo Nordisk rather than a driver of near-term trading in its shares. Investors will be watching how the data hold up under regulatory review and how much room the drug can carve out in treating a rare disease.
market impact
Novo Nordisk: the filing extends its pipeline, but regulatory decisions are not expected until 2027
tags
instruments
sources
- Novo Seeks FDA, EMA Approval for Once-Daily Sickle Cell Therapy Etavopivat — Reuters, 13 November 2026 at 11:06 UTC
- Novo Seeks FDA, EMA Approval for Once-Daily Sickle Cell Therapy Etavopivat — Reuters, 13 November 2026 at 11:48 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗